Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.85 SEK | -0.62% | -3.51% | -5.57% |
May. 14 | Transcript : C-Rad AB, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | C-Rad AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.57% | 125M | C | ||
+12.15% | 227B | B | ||
+14.90% | 197B | B- | ||
+18.22% | 141B | B- | ||
+29.15% | 110B | A- | ||
+0.53% | 64.15B | A- | ||
+16.92% | 53.72B | B+ | ||
+6.33% | 51.75B | B+ | ||
+10.93% | 45.2B | A | ||
+5.87% | 37.37B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRAD B Stock
- Ratings C-Rad AB